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Abstract
Background: Topical phenytoin is a powerful skin wounds healing and it may be useful in clinical practice. The
purpose of this study was to evaluate the effect of topical phenytoin 0.5%, by comparing it with cream (control) in
wounds resulting from excision of two melanocytic nevi in the same patient. Our purpose was also to assess if
phenytoin had better therapeutic and cosmetic outcomes when compared with cream (control).
Methods: This study evaluated 100 patients with skin wounds from excision of melanocytic nevi. 50 patients with
lesions on the face and 50 patients with lesions on the back, totalizing 200 lesions excised with modified punch.
The resulting superficial skin wounds had the same diameter and depth, and second intention healing followed.
Patients were followed for 60 days. Student’s t-test, Mann Whitney nonparametric test, analysis of variance, LSD
test, Shapiro-Wilks test and Fisher test were used to analyze the results, depending on the nature of the variables
being studied.
Results: Phenytoin showed better therapeutic and cosmetic results, by healing faster, with more intense
epithelization in wounds in comparison with cream (control). Phenytoin showed a statistically significant difference
regarding the following parameters (p < 0.05): wounded area and healing time. Phenytoin application resulted in a
smaller area and a shorter healing time. Also the intensity of exudates, bleeding, and the epithelization were more
intense in phenytoin-treated wounds. Regarding the shape and thickness of the scar, injuries treated with
phenytoin had round and flat shaped scars in most of the cases. Considering patient’s gender and phototype,
female patients presented smaller wounds and scar areas; and phototype I had the largest scar areas. Contact
eczema was an adverse reaction in 7 injuries located on the back caused by cream (control) and hypoallergenic
tape.
Conclusions: Phenytoin showed better therapeutic and cosmetic results compared with cream (control). Phenytoin
is a low cost drug, which accelerates skin wounds healing in human patients. Trial registration: ISRCTN96539803
Background
This paper investigates the use of topical phenytoin in
the treatment of cutaneous wounds resulting from exci-
sion of melanocytic nevi on the face and on the back.
The 5.5-diphenyl-2-4-imidazolidione, sodium (pheny-
toin), was synthesized in 1908, and has been used as an
anticonvulsant, since 1937. It was later noticed that half
the patients treated with phenytoin developed gingival
overgrowth [1]. Local use of phenytoin speeds the heal-
ing process of cutaneous wounds. There are no studies
using topical phenytoin (Table 1) in surgical wounds of
human patients who returned for evaluation in 7, 14, 21
days (cosmetic outcome in the mediate postsurgical 60
days). Despite advances in skin healing treatments and
the outbreak of new therapies, the treatment of trophic
ulcers and wounds originated from the resection of skin
tumors, remains a great challenge for doctors and
patients. New therapeutic agents that improve the tissue
repair process are needed, reducing healing time and
preventing the formation of cheloids and retractile scar
tissue. Those should also be cost effective and well
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systemic absorption [2].
Methods
This blind, non-randomized, prospective, longitudinal,
comparative study was performed in 100 patients, by
resection of two lesions clinically compatible with mela-
nocytic nevi measuring 0.4 to 0.6 cm in diameter. There
were 50 patients with lesions on the face and 50 patients
with lesions on the back, totalizing 200 lesions. All the
patients read and signed an informed consent approved
by the Institution’s Ethics Committee
Treatment methodology: inclusion criteria were
healthy individuals of both sexes. This study included 29
male and 71 female patients, ranging from 16 to 77
years old, treated at Hospital Santa Casa de Misericór-
dia, in Curitiba. Inclusion criteria also comprehended
patients being clinically healthy individuals of both
sexes, with two melanocytic nevus lesions located in the
face or back of the thorax, evaluated for possible surgi-
cal removal, when they presented at least one of the fol-
lowing changes: itching, changes in pigmentation,
inflammation, bleeding, localization in an area of
trauma, or aesthetic reasons. Wounds healing process,
cosmetic outcome and possible complications were eval-
uated. All surgical procedures were carried out by the
same dermatologic surgeon. Patients with immunosup-
pression, chronic renal insufficiency, and serious coagu-
lopathies or with history of adverse effects caused by
phenytoin were excluded. Data related to sex, age, skin
type, and location of lesions were collected and are pre-
sented in Table 2. All patients returned for a clinical
and cosmetic evaluation with photographic documenta-
tion in 7, 14, 21 and 60 days. All photographs were
taken from a fixed distance of the wound. Only two
melanocytic nevi of each patient were excised from the
face or the back and received the same postsurgical
treatment. Two nevi lesions with similar diameters,
located on the face and on the back (figures 1 and 2)
were excised with either 6 or 8 mm modified punches,
depending on nevu’s diameter, creating a superficial
cutaneous wound, of same diameter and depth (figures
3 and 4). A modified punch (figure 5) was used for
excising the lesions after local anesthesia with mepiva-
caine (10 mg/ml) + adrenaline (5 μg/ml). A 6 mm
punch was used for lesions up to 0.4 cm and an 8 mm
punch for lesions up to 0.6 cm. The resulting specimens
Table 1 Preparation of a cream containing phenytoin
War N Lanett 20%
Volatile Silicone 2%
Grape seed oil 8%
Sorbitol 10%
Preservatives: (metilparabeno, propilparabeno,
cosmoguard)
q.s
Phenytoin powder 0.5%
Distilled water q.s to 100
g
Table 2 Patients’ details
No. %
Sex
Female 71 71
Male 29 29
Total 100 100
Age (years)
16-77
100 100
Site of the lesion
Face 50 50
Back 50 50
Skin type
I1 7 1 7
II 18 18
III 31 31
IV 12 12
V2 2
* Skin type (Fitzpatrick’s classification) [13]
Figure 1 Intradermal nevus.
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examination. Bleeding was controlled mainly with com-
pression. Hemostasis was achieved using low voltage
electro-fulguration (2 W), in all cutaneous wounds. Fol-
lowing the surgical procedure, the wound was cleaned
with water and soap. One of the injuries received a
wound dressing with phenytoin and the other, a wound
dressing with cream (control). All patients received two
tubes of 20 grams of cream to make the dressing. One
of the tubes containing only cream (control), marked in
red and another tube with phenytoin 0.5%, marked in
black. Patients received a sheet containing guidelines for
wound dressing. Only the doctor knew which tube con-
tained phenytoin. Patients were their own controls in
this study. Full healing was defined as total closure of
the injury without evidence of residual exudates or
inflammation. The efficiency of the method was based
on physician’s evaluations and on comparative photo-
graphic documentation. A software was specially devel-
oped to automatically measure, in square millimeters,
cutaneous wound and scars area, on digital images.
Statistical Analyses
Student’s t-test was used to compare quantitative vari-
ables of two independent groups, and the Mann-Whit-
ney nonparametric test was used for independent
samples. To compare more than two groups, we used
Figure 2 Intradermal nevus.
T=0 T=0
Figure 3 Day of the surgical procedure (zero).
T=0 T=0
Figure 4 Day of the surgical procedure (zero).
6 MM
8 MM
Figure 5 6 and 8 mm Punch.
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test, for multiple comparisons. For paired comparison of
quantitative variables, the Student’s t-test for dependent
samples or the nonparametric test of Wilcoxon were
used. The condition of variables for normality was eval-
uated by Shapiro-Wilks test. For dichotomous nominal
variables, comparisons were made by use of the Fisher
exact test or the binomial test. Values of p <0.05 were
statistically significant.
Results
Regarding epithelization, phenytoin treatment and
cream (control) were statistically different (p < 0.05).
Injuries treated with phenytoin showed more intense
epithelization, with smaller wounded area and shorter
healing time (Table 3 and 4). Considering the area and
shape of the scar, there was a significant statistical dif-
ference in these parameters (p < 0.01). Most injuries
treated with phenytoin were larger with flatter and
round-shaped scars in comparison with injuries treated
with cream. This happened because phenytoin inhibited
skin retraction, leaving a larger scar, but a better cos-
metic outcome. (Table 3 and figures 6 and 7).
Combining patient’s gender with injured and scar
areas, it was possible to establish a statistically signifi-
cant difference for this parameter (p < 0.05). Female
patients presented smaller wounded and scar areas
(Table 5). Combining phototypes and scar area with
matched comparisons of phototypes and scar area, and
also matched comparisons of phototypes (I × II), (I ×
IV), (I × V), there was a statistical significance for this
parameter (p < 0.05), showing the largest scar area for
phototype I (Table 6). Considering presence of bleeding,
hyperemia and exudates in wound, there was a statisti-
cally significant difference for these parameters (p <
0.05). Injuries treated with phenytoin cream had more
bleeding, exudates and hyperemia, probably due to the
Table 3 Results of the evaluation of 100 patients’ wounds on the face and back Chronological data collection
Cream (control) Phenytoin Cream
07
th 14
th 21
th 60
th VARIABLES 07
th 14
th 21 th 60
th
16.97 6.23 1.04 ————— Skin would area
mm
2
14.36 3.82 0.33 —————
———— ———— ———— 13.95 Scar area mm
2 ———— ———— ———— 14.82
D F G H Epithelization
(intensity)
EFGH
0 0 0 0 Hypertrophic
tissue
0000
+ + + 0 Hyperemia ++ ++ + 0
0 0 0 0 Infection 0 0 0 0
+ + 0 0 Bleeding
(intensity)
++ ++ 0 0
———— ————— —————— A - C Shape and
thickness of the
scar
—————— —————— —————— B
———— ++ —————— ————— Adverse reactions.
(allergic
dermatitis)
————— ————— —————— ——————
+ + 0 0 Exudate
(intensity)
++ + 0 0
—————— ————— ——————— good Cosmetic
outcomes
—————— —————— —— excellent
This table was scored on a visual analogue scale: 0 (absent); + (mild); ++ (moderate); +++(severe)
Shape and thickness of the scar using the following scale: A = < 70% elliptic and flat; B = > 70% circular and flat; C = < 10% hypetrophic
For epithelization, the following scale was used: D = < 40% of the wound epithelized; E = > 60% epithelized wound with 6 cases of complete wounds
epithelization; F = > 80% epithelized wound; G = total wound epithelization, thin epidermis; H = total wound epithelization, normal epidermis.
For cosmetic outcomes, the evaluation criteria was: excellent, no noticeable scar, the same color of the surrounding skin and no contractures should be visible;
good, slightly noticeable scar with a different color from the surrounding skin and visible contractures; poor, noticeable scar, presence of depressed and/or
intense dyschromia [10,14].
Adverse reactions (allergic contact dermatitis): ++ (7 cases on the back)
4 cases of contact dermatitis by cream (control) and 03 cases with the hypoallergenic tape
Table 4 Healing time and treatment performed
Cream (control) Phenytoin cream
Healing time
(days)
No. % No. %
70 0 6 6
14 57 57 68 68
21 43 43 26 26
Total 100 100 100 100
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esis. This study found that phenytoin has contributed to
increase the number of capillaries and blood flow, also
increasing exudates and redness, at the edges of the
wound, in the initial phase of wound healing (Table 3).
Just 6 out of the 100 patients had their wounds healed
within a 7-day term. The injuries were on the face.
All wounds received phenytoin application healing in
7 postoperative days, and the re-epitelization was faster
in this group of patients. The patients were female; the
average age was 47 years, three patients with skin type
IV, one with skin type III, and two patients with skin
type I. For excision of nevi three punches of 6 and
8 mm (Table 4 and 7) were utilized. Concerning the
adverse reactions, allergic contact dermatitis occurred in
7 cases, located on the back (Table 8). The cosmetic
outcome was considered excellent by the physician, for
injuries treated with topical phenytoin and, for injuries
treated with cream (control), it was considered good
(Table 3 and figures 4 and 7).
Discussion
In some studies the treatment of skin ulcers used phe-
nytoin diluted in 0.9% NaCl, avoiding the formation of
c r u s ta n db u r n i n gt h a tu s u a l l yr e s u l t sf r o mt h ed i r e c t
application of phenytoin powder [2-4].
In a study with leprosy patients, and those with leg
ulcers, one group was treated with topical phenytoin
sodium suspension at a 2% concentration, and another
group with topical phenytoin sodium suspension at a
C C
P P
T=60
Figure 6 60 days after excision of nevi - P(phenytoin), C(cream
control).
P
C
Figure 7 60 days after excision of nevi - P (phenytoin),
C (cream control).
Table 5 The association between patient’s sex, skin
wound area and scar area
Variables Sex No. Average Minimum Maximum P
value
Skin Wound
area
(7 days)
Female 71 12.99 4.12 30.25
Male 29 17.71 4.22 28.51 0.006
Skin wound
area
(14 days)
Female 71 3.36 0 11.94
Male 29 4.93 0.39 11.10 0.039
Skin wound
area
(21 days)
Female 71 0.29 0 3.97
Male 29 0.45 0 2.40 0.285
Scar area
(60 days)
Female 71 13.88 4.77 23.17
Male 29 17.11 9.66 25.67 0.004
Student’s t-test, for independent samples p < 0.05
Table 6 Skin type (Fitzpatrick’s classification) [13]
Skin type under comparison P value
I × II 0.296
I × III 0.018
I × (IV or V) 0.012
II × III 0.345
II × (IV or V) 0.165
III × (IV or V) 0.503
There are significant differences between skin type and scar area
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difference in the healing time of the ulcers [4].
Topical phenytoin can enhance wound healing in
recalcitrant neuropathic diabetic foot ulcers of patients
with no clinical evidence of ischaemia or infection [5].
In this study, the cream was used as a vehicle for the
preparation of 0.5% topical phenytoin, and the vehicle
cream was the control for the study, constantly hydrat-
ing the wound to avoid crusts or skin irritation. The
author used topical phenytoin in the leg ulcers with
excellent results. Excessive granulation tissue is often a
result of long term phenytoin therapy, but it was not
observed in our study [2,4,6]. All serum concentrations
of phenytoin sodium dosed in patients that received
topical phenytoin in these studies showed quite low or
undetectable serum levels of the drug and the patients
had no adverse effects during treatment [2,3,6]. The
mechanisms by which phenytoin affects healing are
poorly described. There are experimental studies show-
ing that topical administration of phenytoin can pro-
mote wound healing by increasing collagen deposition,
neovascularization, and the expression of growth factors
in the wound tissue [7,8].
With aging, skin gradually loses its structure and func-
tional characteristics, changing the wound healing pro-
cess. Over time, important circulating hormones decline,
steroids, and in particular androgens, play a predomi-
nant role [9]. In-vivo observations indicate that there is
a sex divergence in the healing of acute skin wounds,
and the healing process occurs more slowly in elderly
male than in age-matched female [9].
In the event cosmetic results are not satisfactory for
depressed scars or dyschromia, dermabrasion is an
option to correct these complications. Another option is
to perform a careful curettage, leveling the borders and
the center of the scar. An intralesional infiltration with
corticosteroids is efficient for hypertrophic scars [10].
Considering the effectiveness of phenytoin in acceler-
ating wound healing, improving granulation tissue, redu-
cing bacterial population at the ulcer surface area, and
causing a fast and full healing, we recommend its use as
a safe, effective, easy-to-use form, being also cost effec-
tive in the treatment of ulcers of several etiologies [11].
An experimental work concluded that phenytoin may be
used locally to reduce scars, deformities and contractures
in dystrophic epidermolysis bullosa [12]. In our study,
topical phenytoin reduced, in most of the cases, the con-
tracture of the surgical scar, with a round and flat shape.
Nonetheless, we still need more comparative studies with
other topical treatments to assess cutaneous wounds heal-
ing in human patients in order to confirm their benefits
and clarify their mechanisms of action [1,12].
Conclusions
Phenytoin showed a better therapeutic and cosmetic
outcome in comparison with the cream (control). Phe-
nytoin 0.5% cream is a low-cost drug with pharmacoe-
conomics advantages, which accelerates skin wounds
healing with excellent cutaneous tolerability in human
patients and cosmetic outcome. The dosage of topical
phenytoin is an important variable that needs further
investigation.
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Table 7 Patients with wounds healing in 7 days, using
phenytoin
No. Age
(years)
Sex Site of the
lesion
Skin
type
Punch
(mm)
1 24 Female Face I 6
2 40 Female Face IV 8
3 41 Female Face IV 6
4 45 Female Face I 6
5 61 Female Face III 8
6 62 Female Face IV 8
*Skin type (Fitspatrick’s classification) [13]
Table 8 Adverse reactions, causative agents of allergic
contact dermatitis
Causative agents No. %
Cream (control) 4 57.2
Hypoallergenic tape 3 42.8
Total all adverse reactions 7 100.00
*adverse reactions on the back
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